The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 02, 2025
Filed:
Jan. 22, 2021
Applicant:
Heidelberg Pharma Research Gmbh, Ladenburg, DE;
Inventors:
Anthony Boitano, Newton, MA (US);
Michael Cooke, Boston, MA (US);
Assignee:
Heidelberg Pharma Research GmbH, Ladenburg, DE;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 38/07 (2006.01); A61K 38/12 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/41 (2025.01); A61K 40/50 (2025.01); A61K 47/64 (2017.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); A61P 37/06 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001 (2013.01); A61K 38/07 (2013.01); A61K 38/12 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/418 (2025.01); A61K 47/6415 (2017.08); A61K 47/65 (2017.08); A61K 47/6831 (2017.08); A61K 47/6849 (2017.08); A61P 37/06 (2018.01); A61K 40/50 (2025.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05);
Abstract
The invention provides methods of using allogeneic cells in therapy by combining allogeneic cell therapy with anti-CD137 antibody drug conjugates (ADCs). Disclosed are methods of treating or preventing a host versus graft (HvG) rejection in a human subject receiving allogeneic cell therapy by administering to the human subject an anti-CD137 ADC.